Literature DB >> 2306791

Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain.

N H Greig1, E M Daly, D J Sweeney, S I Rapoport.   

Abstract

Equimolar doses of chlorambucil (10 mg/kg) and the lipophilic chlorambucil derivative, chlorambucil-tertiary butyl ester (13 mg/kg), were given i.v. to rats. Plasma and brain concentrations of chlorambucil and its active metabolites, 3,4-dehydrochlorambucil and phenylacetic mustard, as well as of chlorambucil-tertiary butyl ester were then determined by HPLC between 2 and 240 min after drug administration. Chlorambucil demonstrated a monophasic disappearance from plasma following its administration, with a half-life of 28 min. Significant amounts of phenylacetic mustard were detected after 15 min, and this agent maintained high levels of active compounds in plasma throughout the study. Only low concentrations of chlorambucil and phenylacetic mustard were detected in brain between 2 and 120 min. Following equimolar chlorambucil-tertiary butyl ester administration, it rapidly disappeared from plasma, with a half-life of approximately 2 min, and maintained low plateau concentrations between 15 and 120 min after treatment. It was not detected thereafter, although significant amounts of chlorambucil and phenylacetic mustard were detected throughout the study. Significant amounts of chlorambucil-tertiary butyl ester entered and remained within the brain, achieving a peak concentration at 15 min and disappearing thereafter with a half-life of 37 min. Low levels of chlorambucil and phenylacetic mustard were also detected. Calculated from the areas under the concentration vs time curves of total active compounds derived from chlorambucil and chlorambucil-tertiary butyl ester in brain and plasma, the brain:plasma concentration integral ratios were 0.018 and 0.68, respectively. Following equimolar doses of chlorambucil and chlorambucil-tertiary butyl ester, a 7-fold greater concentration integral was achieved by chlorambucil-tertiary butyl ester in brain at a 5-fold lower plasma concentration integral. Chlorambucil-tertiary butyl ester may be of value in the treatment of brain-sequestered tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306791     DOI: 10.1007/bf00686230

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  30 in total

1.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

2.  Comparative physico-chemical properties, biological effects, and disposition in mice of four nitrogen mustards.

Authors:  D Godenèche; J C Madelmont; M F Moreau; R Plagne; G Meyniel
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Therapeutic potential for blood-brain barrier modification in malignant brain tumor.

Authors:  E A Neuwelt
Journal:  Prog Exp Tumor Res       Date:  1984

4.  Epidemiologic study of primary intracranial neoplasms.

Authors:  J F Annegers; B S Schoenberg; H Okazaki; L T Kurland
Journal:  Arch Neurol       Date:  1981-04

5.  Methotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters.

Authors:  A Rosowsky; R A Forsch; C S Yu; H Lazarus; G P Beardsley
Journal:  J Med Chem       Date:  1984-05       Impact factor: 7.446

6.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

7.  Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.

Authors:  N H Greig; S Genka; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.

Authors:  N H Greig; T T Soncrant; K M Wozniak; S I Rapoport
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

9.  Trends in cancer mortality: US white males and females, 1968-83.

Authors:  D L Davis; J Schwartz
Journal:  Lancet       Date:  1988-03-19       Impact factor: 79.321

10.  Epidemiology of brain tumors: the national survey of intracranial neoplasms.

Authors:  A E Walker; M Robins; F D Weinfeld
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

View more
  14 in total

Review 1.  Determinants of passive drug entry into the central nervous system.

Authors:  M D Habgood; D J Begley; N J Abbott
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

Review 2.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 3.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Computational pharmacokinetic rationale for intra-arterial delivery to the brain.

Authors:  Johann N R Cooke; Jason A Ellis; Shaolie Hossain; Juliane Nguyen; Jeffrey N Bruce; Shailendra Joshi
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

Review 5.  Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?

Authors:  Shailendra Joshi; Jason A Ellis; Eugene Ornstein; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-06-25       Impact factor: 4.130

Review 6.  Targeted drug delivery across the blood-brain barrier using ultrasound technique.

Authors:  Cheri X Deng
Journal:  Ther Deliv       Date:  2010-12

7.  Seizure-promoting effect of blood-brain barrier disruption.

Authors:  Nicola Marchi; Lilyana Angelov; Thomas Masaryk; Vincent Fazio; Tiziana Granata; Nadia Hernandez; Kerri Hallene; Tammy Diglaw; Linda Franic; Imad Najm; Damir Janigro
Journal:  Epilepsia       Date:  2007-02-23       Impact factor: 5.864

8.  Revisiting intra-arterial drug delivery for treating brain diseases or is it "déjà-vu, all over again"?

Authors:  Shailendra Joshi; Jason A Ellis; Charles W Emala
Journal:  J Neuroanaesth Crit Care       Date:  2014-05

9.  Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo.

Authors:  James J Choi; Shougang Wang; Yao-Sheng Tung; Barclay Morrison; Elisa E Konofagou
Journal:  Ultrasound Med Biol       Date:  2010-01       Impact factor: 2.998

Review 10.  Drug targeting to the brain.

Authors:  William M Pardridge
Journal:  Pharm Res       Date:  2007-06-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.